Emmaus, NIT sign Endari distribution agreement
Under the terms of the agreement, Emmaus will receive an upfront payment and a royalty on NIT’s product sales.
Drug Development
How one US state is tackling the drug affordability crisis
Johnson & Johnson acquires Halda Therapeutics for $3.05bn
Innovent receives NMPA approval for Tabosun colon cancer treatment
Gilead Sciences to acquire Repare’s RP-3467
Zydus and Bioeq partner for commercialisation of Nufymco in US
Genentech secures FDA approval for Lunsumio VELO SC for follicular lymphoma
Samsung Biologics to acquire Human Genome Sciences
